S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Nasdaq Climbs on Tech Strength as Dow and Small Caps Retreat

The Nasdaq Composite pushed to a weekly gain fueled by tech sector momentum, even as broader market sentiment soured. While the tech-heavy index surged 1.18% on Friday, the Dow Jones Industrial Average and Russell 2000 lagged, closing the week in the red as investors navigated a landscape of shifting yields and commodity price volatility.

Nasdaq Climbs on Tech Strength as Dow and Small Caps Retreat
Photo: Bio & News

The S&P 500 finished at 7,719.34, failing to hold its previous week's momentum despite a late-session rally. Market focus remained fixed on a narrow leadership group, leaving the Dow Jones Industrial Average to close the week down 1.42% at 51,094.96. Rising interest rates played a role in the broader cooling, with the 10-year Treasury yield climbing 8 basis points over the week to reach 5.26%.

Corporate developments underscored a week of mixed performance. RTX secured a significant $24.4 billion contract for Standard Missile-6 interceptors, while Integra LifeSciences lowered its full-year guidance following flood-related disruptions at its Cincinnati facility. Meanwhile, Axogen signaled a shift in its growth strategy by acquiring BioCircuit Technologies, adding the sutureless nerve repair device NerveTape to its portfolio. Elsewhere, Phillips Edison & Company reaffirmed its 2026 earnings outlook, even as it ramped up its acquisition targets to as much as $700 million.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!